Literature DB >> 27310542

Cancer patients, emergencies service and provision of palliative care.

Bruno Miranda1, Suely Arruda Vidal2, Maria Júlia Gonçalves de Mello3, Jurema Telles de Oliveira Lima4, Judith Correia Rêgo5, Milena Cândido Pantaleão5, Viviane Gomes Carneiro Leão5, Fernando Antônio Ribeiro de Gusmão6, José Iran da Costa7.   

Abstract

OBJECTIVE: To describe the clinical and sociodemographic profile of cancer patients admitted to the Emergency Center for High Complexity Oncologic Assistance, observing the coverage of palliative and home care.
METHOD: Cross sectional study including adult cancer patients admitted to the emergency service (September-December/2011) with a minimum length of hospital stay of two hours. Student's t-test and Pearson chi-square test were used to compare the means.
RESULTS: 191 patients were enrolled, 47.6% elderly, 64.4% women, 75.4% from the city of Recife and greater area. The symptom prevalent at admission was pain (46.6%). 4.2% of patients were linked to palliative care and 2.1% to home care. The most prevalent cancers: cervix (18.3%), breast (13.6%) and prostate (10.5%); 70.7% were in advanced stages (IV, 47.1%); 39.4% without any cancer therapy.
CONCLUSION: Patients sought the emergency service on account of pain, probably due to the incipient coverage of palliative and home care. These actions should be included to oncologic therapy as soon as possible to minimize the suffering of the patient/family and integrate the skills of oncologists and emergency professionals.

Entities:  

Mesh:

Year:  2016        PMID: 27310542     DOI: 10.1590/1806-9282.62.03.207

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

1.  Myiasis associated with an invasive ductal carcinoma of the left breast: case study.

Authors:  Felipe Tavares Rodrigues; Larissa Raquel Klemig; Marcos Roberto Pereira Cardozo; Paulo Cesar Alves; Valéria Magalhães Aguiar; Claudia Soares Lessa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-06-01       Impact factor: 1.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.